Pioneering Precision with ABEmax Technology

An Advanced Adenine Base Editor for Precise Genome Editing - ABEmax
ABEmax represents a significant advancement in the field of genome engineering, enabling highly precise single-nucleotide conversions without inducing DNA double-strand breaks. As an optimized variant of adenine base editors (ABEs), ABEmax mediates efficient and specific A•T to G•C transitions within genomic DNA. This refined molecular tool has become a pivotal platform in genetic research, therapeutic genome editing, and biotechnology innovation.


The molecular mechanism of ABEmax
ABEmax is a gene editing tool that combines an evolved adenine deaminase enzyme (TadA*) with the CRISPR-Cas9 system to achieve precise A-to-G (adenine to guanine) base conversion in DNA. The core mechanism relies on the engineered TadA* enzyme, which specifically catalyzes the deamination of adenine in single-stranded DNA, converting it into inosine. During DNA replication, inosine is interpreted as guanine by the cellular machinery, thereby effectively changing an A·T base pair into a G·C base pair without introducing double-strand breaks.


ABEmax consists of three key components that work synergistically to achieve precise base editing:







ABEmax represents a robust and precise tool for targeted adenine base editing, expanding the scope of possible therapeutic and research applications by enabling correction of many pathogenic point mutations with high specificity and efficiency.